Investment firm Bernstein has revised its price target for Illumina (ILMN, Financial), lowering it from $130 to $90 while maintaining a Market Perform rating on the stock. The decision reflects increasing headwinds in the industry, including tariffs and potential funding issues from the National Institutes of Health (NIH) and broader academic and government sectors. Additionally, ongoing impacts from Health and Human Services (HHS) policies affecting pharmaceutical companies are causing concern.
Bernstein notes that while they initially anticipated a recovery in the tools sector earlier this year, current indicators suggest otherwise. The firm points out that the expected risks have begun to manifest in actual performance metrics as they approach the first quarter. Consequently, Bernstein is adopting a cautious stance toward Illumina heading into the new quarter.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 22 analysts, the average target price for Illumina Inc (ILMN, Financial) is $120.41 with a high estimate of $190.00 and a low estimate of $75.00. The average target implies an upside of 61.43% from the current price of $74.59. More detailed estimate data can be found on the Illumina Inc (ILMN) Forecast page.
Based on the consensus recommendation from 25 brokerage firms, Illumina Inc's (ILMN, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Illumina Inc (ILMN, Financial) in one year is $158.34, suggesting a upside of 112.28% from the current price of $74.59. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Illumina Inc (ILMN) Summary page.
